INSM Stock Analysis: Insmed | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 28.731m USD | 12M Return: 17.4% | US4576693075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 302M
Qual. Beats: 0
Rev. Trend: 90.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases across the United States, Europe, Japan, and other international markets. The companys lead commercial product is ARIKAYCE, used to treat refractory nontuberculous mycobacterial lung infections, which is also being evaluated in a Phase 3 trial for mycobacterium avium complex lung disease as part of a combination antibacterial regimen.
Insmeds pipeline includes brensocatib, an oral DPP1 inhibitor in Phase 3 development for bronchiectasis and Phase 2 trials for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. The company is also advancing treprostinil palmitil inhalation powder, in Phase 3 for pulmonary hypertension associated with interstitial lung disease, alongside earlier-stage gene therapy candidates, including INS1201 for Duchenne muscular dystrophy and INS1202 for amyotrophic lateral sclerosis, as well as a monoclonal antibody (INS1148) targeting stem cell factor for interstitial lung disease and asthma.
Insmed was founded in 1988 and is headquartered in Bridgewater, New Jersey, and operates within the biotechnology sub-industry of the healthcare sector. The companys business model reflects a typical rare disease biotech approach, combining a single approved product generating revenue with a pipeline concentrated in late-stage clinical development targeting indications with limited existing treatment options.
- ARIKAYCE sales growth drives refractory NTM lung infection revenue
- Brensocatib phase 3 bronchiectasis trial readout as key catalyst
- Treprostinil palmitil phase 3 results in PH-ILD patients
| Net Income: -875.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.42 > 0.02 and ΔFCF/TA -4.76 > 1.0 |
| NWC/Revenue: 105.1% < 20% (prev 444.6%; Δ -339.5% < -1%) |
| CFO/TA -0.48 > 3% & CFO -1.00b > Net Income -875.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (217.4m) vs 12m ago 14.82% < -2% |
| Gross Margin: 83.27% > 18% (prev 75.72%; Δ 7.56% > 0.5%) |
| Asset Turnover: 49.65% > 50% (prev 16.05%; Δ 33.60% > 0%) |
| Interest Coverage Ratio: -9.72 > 6 (EBIT TTM -790.5m / Interest Expense TTM 81.3m) |
| A: 0.57 (Total Current Assets 1.63b - Total Current Liabilities 438.7m) / Total Assets 2.10b |
| B: -2.76 (Retained Earnings -5.81b / Total Assets 2.10b) |
| C: -0.35 (EBIT TTM -790.5m / Avg Total Assets 2.29b) |
| D: 0.56 (Book Value of Equity 757.5m / Total Liabilities 1.35b) |
| Altman-Z'' = -7.01 = D |
| DSRI: 1.37 (Receivables 215.3m/55.0m, Revenue 1.14b/398.1m) |
| GMI: 0.91 (GM 75.72% / 83.27%) |
| AQI: 1.40 (AQ_t 0.16 / AQ_t-1 0.11) |
| SGI: 2.86 (Revenue 1.14b / 398.1m) |
| TATA: 0.06 (NI -875.3m - CFO -1.00b) / TA 2.10b) |
| Beneish M = -1.23 (Cap -4..+1) = D |
As of August 12, 2026, the stock is trading at USD 132.57 with a total of 2,253,227 shares traded. Over the past week, the price has changed by +34.25%, over one month by +21.47%, over three months by +27.61% and over the past year by +17.43%.
Current recommended Stop Loss: 124.90 (which is 5.8% or 1.2 ATR below the current price).
Insmed has received a consensus analysts rating of 4.81. Therefore, it is recommended to buy INSM.
- StrongBuy: 17
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 196 | 47.8% |
P/E Forward = 16.3666
P/S = 35.0559
P/B = 30.3671
P/EG = 1.0916
Revenue TTM = 1.14b USD
EBIT TTM = -790.5m USD
EBITDA TTM = -770.0m USD
Long Term Debt = 541.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 588.9m USD (corrected: LT Debt 541.0m + ST Debt 9.81m) + Leases 38.1m
Net Debt = -205.0m USD (calculated: Debt 588.9m - CCE 793.9m)
Enterprise Value = 28.5b USD (28.7b + Debt 588.9m - CCE 793.9m)
Interest Coverage Ratio = -9.72 (Ebit TTM -790.5m / Interest Expense TTM 81.3m)
EV/FCF = -32.67x (Enterprise Value 28.5b / FCF TTM -873.0m)
FCF Yield = -3.06% (FCF TTM -873.0m / Enterprise Value 28.5b)
FCF Margin = -76.74% (FCF TTM -873.0m / Revenue TTM 1.14b)
Net Margin = -76.94% (Net Income TTM -875.3m / Revenue TTM 1.14b)
Gross Margin = 83.27% ((Revenue TTM 1.14b - Cost of Revenue TTM 190.3m) / Revenue TTM)
Gross Margin QoQ = 84.20% (prev 83.82%)
Tobins Q-Ratio = 13.57 (Enterprise Value 28.5b / Total Assets 2.10b)
Interest Expense / Debt = 13.81% (Interest Expense 81.3m / Debt 588.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -624.5m (EBIT -790.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.19 (Total Current Assets 1.63b / Total Current Liabilities 512.1m)
Debt / Equity = 0.78 (Debt 588.9m / totalStockholderEquity, last quarter 757.5m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -205.0m / EBITDA -770.0m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -205.0m / FCF TTM -873.0m)
Total Stockholder Equity = 786.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.20% (Net Income -875.3m / Total Assets 2.10b)
RoE = -111.3% (Net Income TTM -875.3m / Total Stockholder Equity 786.7m)
RoCE = -59.54% (EBIT -790.5m / Capital Employed (Equity 786.7m + L.T.Debt 541.0m))
RoIC = -38.63% (negative operating profit) (NOPAT -624.5m / Invested Capital 1.62b)
WACC = 7.01% (E(28.7b)/V(29.3b) * Re(6.93%) + D(588.9m)/V(29.3b) * Rd(13.81%) * (1-Tc(0.21)))
Discount Rate = 6.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.37 | Cagr: 18.46%
[DCF] Fair Price = unknown (Cash Flow -873.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.59 | # QB: 0
Revenue Correlation: 90.22 | Revenue CAGR: 54.03% | SUE: 3.61 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.60 | Chg30d=+1.31% | Revisions=+22% | Analysts=15
EPS current Year (2026-12-31): EPS=-2.63 | Chg30d=+2.00% | Revisions=+30% | GrowthEPS=+59.0% | GrowthRev=+181.8%
EPS next Year (2027-12-31): EPS=0.16 | Chg30d=+29.49% | Revisions=-10% | GrowthEPS=+105.9% | GrowthRev=+62.9%
[Analyst] Revisions Ratio: +17% (up=12, down=8)